Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127259 | 0.82 | ATM (1.00) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL6052462 | 0.81 | ATM (0.69) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL28775954 | 0.81 | ATM (0.69) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL1419333 | 0.81 | ATM (0.69) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL6634976 | 0.81 | ATM (0.69) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL25240419 | 0.81 | ATM (0.69) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL25286936 | 0.80 | ATM (0.62) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL28256156 | 0.79 | ATM (0.61) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL4001880 | 0.78 | ATM (0.65) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 | |
| SCHEMBL27363470 | 0.78 | ATM (0.65) | ATMALDH1A1CYP1A2L3MBTL1TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066347-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | MEDIFIC, INC. (KR) | 2025-02-27 | — | — | US | disclosed |
| EP-4455143-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | Medific, Inc. (KR) | 2024-10-30 | — | — | EP | disclosed |
| CN-118591539-A | Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same | (株)美迪菲 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023121184-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121184-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| CN-111943935-A | Prolinol rapid desulfurizing agent and preparation method thereof | 西安工业大学 | 2020-11-17 | — | — | CN | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-5451597-A | Hypotensive agents, congestive heart failure | G.D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5389641-A | Fused heterocyclic compounds, having angiotensin II antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| US-5215994-A | Treating or preventing hypertension or heart failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| US-5210092-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-11 | — | — | US | disclosed |
| US-5187271-A | Hypotensive agents, cardiovascular disorders | G. D. SEARLE & CO. (US) | 1993-02-16 | — | — | US | disclosed |
| US-5175180-A | Antagonist, antagonism | G. D. SEARLE & CO. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0518033-A1 | Fused heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992015577-A1 | N-SUBSTITUTED (ALPHA-IMIDAZOLYL-TOLUYL) PYRROLE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | disclosed |
| WO-1992011255-A1 | N-SUBSTITUTED N-(α-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-07-09 | — | — | WO | disclosed |
| EP-0480204-A1 | Imidazole derivatives, potent and selective antagonists of angiotensin II receptor | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | ATM 444/4885ALDH1A1 2424/4885CYP1A2 4596/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | ATM 2001/4885ALDH1A1 3670/4885CYP1A2 4773/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | ATM 887/4885ALDH1A1 1723/4885CYP1A2 1667/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | ATM 2001/4885ALDH1A1 3670/4885CYP1A2 4773/4885 |
| US-20250066347-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | SREBF1, SREBF2, SP1 | ATM 914/4885ALDH1A1 1168/4885CYP1A2 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.